OmnimAbs is a globally leading antibody discovery technology platform company, dedicated to providing fully human antibody development solutions for biopharmaceutical companies. The company relies on its proprietary genetically modified animal platform, such as OmniRat ®、 OmniMouse ®、 OmniChicken ®） And advanced in vitro screening techniques such as OmniSeq ®、 OmniDeep ®）， Significantly improve the efficiency and success rate of antibody drug discovery. At present, over 45 antibody drugs developed based on OmniAb technology have entered the clinical stage, covering multiple therapeutic fields such as tumors, autoimmune diseases, and infectious diseases.

In recent years, OmnimAbs has continuously expanded its global cooperation network and reached strategic partnerships with many well-known pharmaceutical companies such as Novartis, GlaxoSmithKline, and Simcere Pharmaceuticals. After being spun off and independently listed from Ligand Pharmaceuticals in 2022, the company further increased its investment in AI driven antibody optimization and expanded into cutting-edge fields such as bispecific antibodies and T cell adapters. With its efficient and flexible technology platform, OmniAb is accelerating the development of next-generation antibody therapies and consolidating its leading position in antibody discovery.